Throughout this medical market research, the publisher analyzed 28 orthobiologics companies in China and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.
While this MedSuite report contains all of the China Orthopedic Biomaterials market analysis, each of the market segments is also available as stand-alone MedCore reports. Additionally, this research includes an orthobiologics procedure volume analysis which can also be purchased as a separate report, MedPro.
Markets Covered
China Orthopedic Biomaterials Market Insights
Surgical procedures that require the use of orthopedic biomaterials are generally associated with diseases and indications that become more prevalent in the population with an increase in age, such as osteoarthritis of the spine and knee. In 2019, approximately 12% of the Chinese population was aged 65 and over; this proportion is projected to grow steadily over the forecast period, as further cohorts of baby boomers turn 65.
In the past, lower tier hospitals (I and II) were primarily served by local manufacturers with relatively simple products at significantly lower prices than the products purchased by tier III hospitals, which were primarily supplied by international companies. Now, with the financial and regulatory support of the government, increasingly difficult entry barriers for international products and weak intellectual property protection that incentivizes product plagiarism, the market has shifted in favor of local manufacturers.
Overall, the China orthopedic biomaterials market was valued at $460.7 million in 2019. This is expected to increase over the forecast period at a CAGR of 6% to reach $690.8 million.
While this MedSuite report contains all of the China Orthopedic Biomaterials market analysis, each of the market segments is also available as stand-alone MedCore reports. Additionally, this research includes an orthobiologics procedure volume analysis which can also be purchased as a separate report, MedPro.
Markets Covered
- Procedure Volumes for the China Orthopedic Biomaterials Devices – MedPro
- Orthopedic Bone Graft Substitute Market - MedCore
- Orthopedic Growth Factor Market - MedCore
- Hyaluronic Acid Viscosupplementation Market - MedCore
China Orthopedic Biomaterials Market Insights
Surgical procedures that require the use of orthopedic biomaterials are generally associated with diseases and indications that become more prevalent in the population with an increase in age, such as osteoarthritis of the spine and knee. In 2019, approximately 12% of the Chinese population was aged 65 and over; this proportion is projected to grow steadily over the forecast period, as further cohorts of baby boomers turn 65.
In the past, lower tier hospitals (I and II) were primarily served by local manufacturers with relatively simple products at significantly lower prices than the products purchased by tier III hospitals, which were primarily supplied by international companies. Now, with the financial and regulatory support of the government, increasingly difficult entry barriers for international products and weak intellectual property protection that incentivizes product plagiarism, the market has shifted in favor of local manufacturers.
Overall, the China orthopedic biomaterials market was valued at $460.7 million in 2019. This is expected to increase over the forecast period at a CAGR of 6% to reach $690.8 million.
Table of Contents
LIST OF FIGURESLIST OF CHARTSABBREVIATIONS
EXECUTIVE SUMMARY
RESEARCH METHODOLOGY
CHINESE ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW
PROCEDURE NUMBERS
BONE GRAFT SUBSTITUTE MARKET
HYALURONIC ACID VISCOSUPPLEMENTATION MARKET
ORTHOPEDIC GROWTH FACTOR MARKET
APPENDIX: LOCAL COMPETITOR DIRECTORY
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allgens Medical
- Biocomposites
- Biolu Biomaterials
- Bloomage Freda Biopharm
- Datsing Bio-tech
- DePuy Synthes
- FocusChem
- Genzyme
- Guona Keji
- Haghzhou Gallop
- Harbin Gloria Pharmaceutical
- Jinxingda Company (Tianjin)
- Kunming Baker Norton
- Medtronic
- Novabone
- Osteolink Biomaterials (Lianjie Company)
- Seikagaku
- Shanghai Anjiu Biotechnology
- Shanghai HaoHai
- Shanghai Jingfeng Pharmaceutical
- Shanghai Rebone Biomaterials
- Shanxi OsteoRad Biomaterials
- Wright Medical
- Xin Kang Chen
- Yunkanghengye Company
